Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.10037 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 10037-10037 ◽

Cited By ~ 1

Author(s):

H. Gelderblom ◽

J. Blay ◽

B. M. Seddon ◽

M. Leahy ◽

I. L. Ray-Coquard ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Bone Sarcoma ◽

First Line ◽

Randomized Phase Ii ◽

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

European Journal of Cancer ◽

10.1016/j.ejca.2006.09.014 ◽

2007 ◽

Vol 43 (2) ◽

pp. 308-315 ◽

Cited By ~ 35

Author(s):

Michael Leahy ◽

Isabelle Ray-Coquard ◽

Jaap Verweij ◽

Axel Le Cesne ◽

Florence Duffaud ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Bone Sarcoma ◽

European Organisation ◽

Potential Activity

Results of a Randomised Phase III Trial (EORTC 62012) of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide as First Line Chemotherapy for Patients with Advanced or Metastatic Soft Tissue Sarcoma: A Survival Study by the Eortc Soft Tissue and Bone Sarcoma Group

Annals of Oncology ◽

10.1016/s0923-7534(20)34351-9 ◽

2012 ◽

Vol 23 ◽

pp. ixe28 ◽

Cited By ~ 7

Author(s):

I. Judson ◽

J. Verweij ◽

H. Gelderblom ◽

J.T. Hartmann ◽

P. Schöffski ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Single Agent ◽

Bone Sarcoma ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Survival Study ◽

1652P A prospective, single-arm phase II study of pegylated-liposome doxorubincin combined with ifosfamide as first-line treatment for patients with advanced or metastatic soft tissue sarcoma

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1878 ◽

2020 ◽

Vol 31 ◽

pp. S986

Author(s):

X. Liu ◽

X. Zhang ◽

J. Cao ◽

H. Wang ◽

X. Wu ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Pegylated Liposome ◽

First Line Treatment

Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.9011 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 9011-9011

Author(s):

P. M. Deckert ◽

J. M. Siehl ◽

E. Thiel ◽

A. Schmittel ◽

G. Hütter ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Liposomal Daunorubicin ◽

Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.10031 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 10031-10031 ◽

Cited By ~ 7

Author(s):

P. Schoffski ◽

I. L. Ray-Coquard ◽

A. Cioffi ◽

N. Bin Bui ◽

S. Bauer ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Bone Sarcoma ◽

Eribulin Mesylate ◽

European Organisation ◽

Phase Ii Studies

3439 Prognostic factors in soft tissue sarcoma patients with lung metastases only receiving first-line chemotherapy. An exploratory, retrospective analysis on fifteen trials of the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)

European Journal of Cancer ◽

10.1016/s0959-8049(16)31912-8 ◽

2015 ◽

Vol 51 ◽

pp. S701

Author(s):

L. Lindner ◽

S. Litiere ◽

S. Sleijfer ◽

I. Judson ◽

A. Italiano ◽

...

Keyword(s):

Prognostic Factors ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Retrospective Analysis ◽

Lung Metastases ◽

Bone Sarcoma ◽

First Line ◽

European Organization ◽

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study

Annals of Oncology ◽

10.1093/annonc/mdq338 ◽

2011 ◽

Vol 22 (1) ◽

pp. 207-214 ◽

Cited By ~ 104

Author(s):

J.R. Kroep ◽

M. Ouali ◽

H. Gelderblom ◽

A. Le Cesne ◽

T.J.A. Dekker ◽

...

Keyword(s):

Prognostic Factor ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Peripheral Nerve ◽

Bone Sarcoma ◽

Nerve Sheath Tumor ◽

First Line ◽

Peripheral Nerve Sheath Tumor ◽

Nerve Sheath ◽

Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.05.016 ◽

2016 ◽

Vol 142 (1) ◽

pp. 95-101 ◽

Cited By ~ 7

Author(s):

I. Ray-Coquard ◽

E. Rizzo ◽

J.Y. Blay ◽

P. Casali ◽

I. Judson ◽

...

Keyword(s):

Clinical Trials ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Bone Sarcoma ◽

Uterine Sarcoma ◽

First Line ◽

Faculty Opinions recommendation of Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1160744.622149 ◽

2009 ◽

Author(s):

Florence Duffaud

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Angiogenesis Inhibitor ◽

Bone Sarcoma ◽

Advanced Soft Tissue Sarcoma ◽

European Organisation